News >

FDA Grants Priority Review to Rucaparib for mCRPC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Jan 15, 2020

Patrick J. Mahaffy, president and CEO of Clovis Oncology

Patrick J. Mahaffy

The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for rucaparib (Rubraca) for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castration-resistant prostate cancer (mCRPC).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication